Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Raxone

Roche - Basel

CHMP turns down Avastin for brain cancer

Roche set to be denied expanded use for oncology drug in Europe

- PMLiVE

CHMP backs European approval for six new medicines

Recommends drugs by PTC Therapeutics, Roche, Biogen Idec, Octapharma, Alcon and Veloxis Pharma

- PMLiVE

Teva backs laquinimod for MS despite CHMP rejection

EMA confirms negative opinion after re-examination

- PMLiVE

Santhera closer to filing for muscular dystrophy drug

Catena/Raxone slows loss of lung function in late stage trial

- PMLiVE

Bayer’s Nexavar recommended for thyroid cancer in EU

CHMP backs extra indication for cancer drug

- PMLiVE

GSK’s Mekinist on course for EU melanoma approval

Only new medicine recommended in latest CHMP opinions

- PMLiVE

EMA backs Janssen rare disease drug for approval

Castleman's disease treatment Sylvant wins CHMP recommendation

- PMLiVE

Boehringer/Lilly’s empagliflozin among CHMP recommendations

If approved it will be marketed as Jardiance

- PMLiVE

Teva’s Symbicort generic backed for EU approval

AstraZeneca braces for competition to COPD drug

- PMLiVE

GSK’s Anoro backed in Europe for COPD

CHMP recommendation set to expand pharma company’s respiratory portfolio

- PMLiVE

EMA brings transparency to its committee proceedings

Publishes meeting minutes of CHMP and two other advisory groups

- PMLiVE

CHMP turns down drugs for MS, cancer and muscular dystrophy

Negative EU recommendations for Teva, AB Science and PTC Therapeutics

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links